Company Description: NemaGen Discoveries is a New Jersey-based biotechnology company that is advancing therapies for patients suffering from allergic disorders and pulmonary fibrosis. The initial therapeutic that NemaGen is developing is a small molecule inhibitor that prevents the development of allergic disorders, such as systemic mastocytosis, food allergy, and asthma, by safely blocking mast cell development from mast cell progenitor cells through targeting the enzyme, carbonic anhydrase 1 (Car1). Thirty-two million Americans suffer from these diseases, which result in $56 billion dollars in healthcare related expenses each year. Only 0.1% of these patients (those with severe disease) have access to a drug that impairs mast cell development because of the poor safety profile of current mast cell targeted therapies. NemaGen’s Car1 inhibitor has the potential to provide broad access to a mast cell targeted therapy due to the well-known exceptional safety profiles of Car enzyme inhibitors. Additionally, NemaGen is building a platform centered around targeting carbonic anhydrases and has an early pipeline program for idiopathic pulmonary fibrosis, by targeting carbonic anhydrase 4.